Fig. 2
From: Toward population specific and personalized treatment of Helicobacter pylori infection
Predicted efficacies of different regimens according to prevalence of (a) clarithromycin resistance and (b) metronidazole resistance. T7: triple therapy for 7Â days; T10: triple therapy for 10Â days; T14: triple therapy for 14Â days; S10: sequential therapy for 10Â days; S14: sequential therapy for 14Â days; C5: concomitant therapy for 5Â days; C7: concomitant therapy for 7Â days; C10: concomitant therapy for 10Â days; H14: hybrid therapy for 14Â days; BQ10: bismuth quadruple therapy for 10Â days; BQ14: bismuth quadruple therapy for 14Â days